Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...
Chertsey, England (ots/PRNewswire) - Experts say the knock-on effect of lack of planning for later life, as highlighted in poll conducted for this year's ASTELLAS INNOVATION DEBATE[TM],will further impact upon stretched NHS resources Results from a new survey for the annual Astellas Innovation Debate have ...
London (ots/PRNewswire) - Astellas Pharma Europe Ltd. today announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the placebo-controlled Phase 3 PREVAIL trial of ...
Tokyo (ots/PRNewswire) - Astellas Pharma Inc. today announces the submission of a variation to amend the Marketing Authorisation Application for XTANDI(TM) (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic ...
Tokyo And San Francisco (ots/PRNewswire) - - Study will be stopped early and enzalutamide offered to all qualified study participants - 30% Reduction in the Risk of Death, Hazard Ratio = 0.70 ...
Chertsey, England (ots/PRNewswire) - - For Healthcare and Business Media - Approval allows for more flexible approach to 8% capsaicin patch treatment of peripheralneuropathic pain The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before ...
Chertsey, England (ots/PRNewswire) - A new treatment, BETMIGA(TM) (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive bladder (OAB) symptoms in adults.[1] Mirabegron represents the first new class of oral treatment in OAB for over 30 years. Currently around half of patients discontinue OAB treatment after only three ...
Chertsey, England (ots/PRNewswire) - Spectacular New Facilities, in Chertsey, Designed by Sir Norman Foster Astellas Pharma Europe Ltd. (APEL), the European Headquarters of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, today formally opens its new office in Hillswood Business Park, Chertsey. To accommodate the company's ...
Chertsey, England (ots/PRNewswire) - ASTELLAS PHARMA EUROPE Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorisation for BETMIGA[TM] (mirabegron) for the symptomatic treatment of urgency, increased micturition ...
Staines, England (ots/PRNewswire) - ASTELLAS PHARMA EUROPE Ltd., the European subsidiary of Tokyo - based Astellas Pharma Inc. today announced the submission of a Market Authorisation Application for EC905 in the Netherlands. This application for approval is the first step of the European-wide mutual recognition ...
Paris (ots/PRNewswire) - ASTELLAS PHARMA EUROPE Ltd., European subsidiary of Tokyo-based Astellas Pharma Inc. today announced results from three separate clinical trials that further support the efficacy and tolerability of mirabegron. Mirabegron, a beta3 adrenoceptor agonist, is the first in a new class of ...
Staines, England (ots/PRNewswire) - Astellas Pharma Inc. [http://www.astellas.com/en/corporate ] today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron (generic name / code name: YM178) to the U.S. Food and Drug Administration and the European Medicines Agency. ...
London (ots/PRNewswire) - Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor. The study is evaluating AC220 as an oral, once-a-day, monotherapy treatment in acute myeloid ...
Staines, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of marketing authorisation for VIBATIV (telavancin hydrochloride) for the ...
London (ots/PRNewswire) - New survey data released today demonstrate that childhood eczema can have a detrimental effect on quality of life not only for the children who live with the disease, but also for their families.[1a] The survey, which was carried out in eight countries across Europe, examines the impact of ...
LONDON, STAINES, England and SAN FRANCISCO, March 30, 2011 (ots/PRNewswire) -- Astellas Pharma Europe Ltd. and Medivation, Inc. today announced treatment of the first patient in the TERRAIN trial, a Phase 2 comparison of the investigational drug MDV3100, a triple-acting, oral androgen receptor antagonist, with ...
Tokyo (ots/PRNewswire) - Astellas Pharma Inc. (http://www.astellas.com/en/corporate/) today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition.(1,2) These data were presented for the ...
London and Staines, England (ots/PRNewswire) - New research by Astellas Pharma Europe Ltd. today reveals the top three challenges facing urologists across Europe are a lack of funding for research and development; a lack of understanding amongst referrers; and a lack of new treatments available to patients.(1) When asked to rank the biggest challenges in urology today, ...
Staines, England (ots/PRNewswire) - Astellas Pharma Europe Ltd. announced today that it has entered into an exclusive collaboration and license agreement with Optimer Pharmaceuticals Inc., San Diego for the development and commercialisation of fidaxomicin, an investigational antibiotic for Clostridium difficile infection (CDI) in Europe and certain other countries ...
Tokyo (ots/PRNewswire) - Astellas Pharma Inc. announced today that its European subsidiary Astellas Pharma Europe Ltd.("Astellas Pharma Europe", headquarters: Stains, U.K.)" acquired the license for commercialization of the treatment for advanced prostate cancer Eligard(R) from TOLMAR Inc. ("TOLMAR", headquarters: Colorado, U.S.A.) on December 22, 2010 in a selection of Asian, Middle Eastern, North African and ...
London, April 20, 2010 (ots/PRNewswire) - Today, on the fifth anniversary since its formation, Astellas Pharma Europe has confirmed that it will continue its emphasis on transplantation and urology while moving towards a new vision to build a strong presence in oncology. Astellas has shown robust growth since its creation, expanding its reach into new therapeutic ...
Barcelona, Spain (ots/PRNewswire) - - New Survey Highlights Need for Education Resources, Critical Role of Physician in Patient Communication and Importance of Maintaining Normal Lifestyle During Treatment Findings from a survey of European prostate cancer patients, presented at the 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC) in ...
San Mateo, California and Staines, England (ots/PRNewswire) - - Conference Call Today at 9:00am ET - Covers Europe, Middle East and Africa - Includes Licensing Option and Development Funding for NGX-1998 NeurogesX, Inc. (NASDAQ: NGSX) and Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo based Astellas Pharma Inc. announced ...
Prague (ots/PRNewswire) - - Ointment (Tacrolimus Monohydrate) in a New Twice-Weekly Regimen can Help Prevent Eczema Flares Today sees the European launch of the first topical calcineurin inhibitor to be approved for the maintenance treatment of eczema to prevent flares and prolong flare-free intervals. ...
Staines, England (ots/PRNewswire) - - Not for distribution in the United Kingdom - Research Adds to Already Demonstrated Efficacy in Adult Population Parents and paediatricians are today welcoming the results of new research that adds additional support for an effective and well tolerated treatment ...
Staines, England (ots/PRNewswire) - The European Medicines Agency (EMEA) has announced the marketing authorisation of Mycamine(R), Astellas Pharma Europe's treatment for invasive candidiasis, oesophageal candidiasis and prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. Mycamine(R) will initially be available ...
Staines, England (ots/PRNewswire) - - New Treatment Option Contributes to Fight Against Healthcare Associated Infections Astellas Pharma Europe Ltd(i) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion by ...
London (ots/PRNewswire) - Astellas today announced that Advagraf(R) (generic name: tacrolimus, prolonged release), a once-daily immunosuppressant for use in organ transplantation, is now available in Germany and the UK. The European Commission approved Advagraf(R) on April 23, 2007 for the prophylaxis of ...
London (ots/PRNewswire) - Astellas announced today that the European Commission has approved the immunosuppressant Advagraf(R) (generic name: tacrolimus, prolonged release) for prophylaxis of transplant rejection in adult kidney or liver allograft recipients and for the treatment of allograft rejection ...